

**Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities Grid**

The AAP CME program aims to develop, maintain, and increase the competency, skills, and professional performance of pediatric healthcare professionals by providing high quality, relevant, accessible and cost-effective educational experiences. The AAP CME program provides activities to meet the participants' identified education needs and to support their lifelong learning towards a goal of improving care for children and families (*AAP CME Program Mission Statement, August 2004*).

The AAP recognizes that there are a variety of financial relationships between individuals and commercial interests that require review to identify possible conflicts of interest in a CME activity. The "AAP Policy on Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities" is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and resolving all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. The AAP has taken steps to resolve any potential conflicts of interest.

All AAP CME activities will strictly adhere to the *2004 Updated Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support: Standards to Ensure the Independence of CME Activities*. In accordance with these Standards, the following decisions will be made free of the control of a commercial interest: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to resolve them prior to the CME activity are implemented in ways that are consistent with the public good. The AAP is committed to providing learners with commercially unbiased CME activities.

**Activity Title:** Pediatrics in Review  
**Activity Location:** Online & Print  
**Activity Dates:** January 2007 – December 2007

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

*All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no relevant financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in CME activities. \*Commercial interest(s) is defined as any proprietary entity producing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies.*

Name	Relevant Financial Relationship (Please indicate Yes, or No)	Name of Commercial Interest(s)* (Please list name(s) of proprietary entity) <u>AND</u> Nature of Relevant Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)	CME Content Will Include Discussion/ Reference to Commercial Products/Services (Please indicate Yes, No, or Not Sure)	Disclosure of Off-Label (Unapproved)/Investigational Uses of Products AAP CME faculty are required to disclose to the AAP and to learners when they plan to discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.  (Do intend to discuss or Do not intend to discuss)
Lawrence F. Nazarian, MD, FAAP, Editor	No	None	Pharmaceuticals and other therapies preferentially identified generically. Occasionally brand names will be used, identifying manufacturer, and more than one will be listed if applicable.	Do intend to discuss but will identify off-label use.
Tina L. Cheng, MD, MPH, FAAP, Associate Editor	No	None	Usually "No" but could on occasion	Do not intend to discuss.
Joseph A. Zenel, MD, FAAP, Associate Editor	No	None	No	Do not intend to discuss.
Henry M. Adam, MD, FAAP, Editor, In Brief	No	None	Not sure	Do not intend to discuss.
Janet R. Serwint, MD, FAAP, Consulting Editor	No	Maternal Child and Health Bureau – research grant	No	Do not intend to discuss.
Laura Ibsen, MD, FAAP, Consulting Editor, Online and Multimedia	No	None	No	Do not intend to discuss.
Robert J. Haggerty, MD, FAAP, Editor Emeritus and Founding Editor	No	None	No	Do not intend to discuss.

Name	Relevant Financial Relationship (Please indicate Yes, or No)	Name of Commercial Interest(s)* (Please list name(s) of proprietary entity) <u>AND</u> Nature of Relevant Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)	CME Content Will Include Discussion/ Reference to Commercial Products/Services (Please indicate Yes, No, or Not Sure)	Disclosure of Off-Label (Unapproved)/Investigational Uses of Products AAP CME faculty are required to disclose to the AAP and to learners when they plan to discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.  (Do intend to discuss or Do not intend to discuss)
Margie Andreae, MD, FAAP	No	None	Not sure	N/A.
Richard Antaya, MD, FAAP	Yes	Astellas Pharma, US, Inc. – speaker bureau, advisory boards, clinical trials; Novartis – speakers bureau	Not sure	Do intend to discuss off-label uses as these are integral to dermatology.
Laurence Boxer, MD, FAAP	Yes	Amgen Stocks – NIH funding	No	Do not intend to discuss.
Latha Chandran, MD, MPH, FAAP	No	None	Yes	Do intend to discuss but will identify off-label use.
Joseph Croffie, MD, MPH, FAAP	Yes	Sucampo Pharmaceuticals (Lubiprostone), Braintree Labs (Miralax, Halflytely), Medtronic (Bravo pH Capsule), Tap pharmaceuticals (Prevacid) – research grant/, speakers Bureau	Not sure	Do not intend to discuss.
Howard Eigen, MD, FAAP	Yes	Astra Zeneca, Merck, GlaxoSmithKline, Teva – speakers bureau for each	N/A	N/A

Leonard Feld, MD, MMM, PhD, FAAP	No	None; speaker and committee member of a Pediatric Board Review Course (sponsored by Ross) through AAP New York	Probably not	Will discuss all drugs used for hypertension, although all drugs do not have pediatric labeling and safety information.
Jeremy N. Friedman, MB, CHB, FAAP	Yes	Proctor & Gamble – Medical Advisory Board, Pampers Parenting Institute	No	Do not intend to discuss.
Vincent A. Fulginiti, MD, FAAP	No	None	No	May discuss, as warranted.
Mark A. Goldstein, MD, FAAP	No	None	No	Do not intend to discuss.
Lindsey K. Grossman, MD, FAAP	No	None	Not sure	Do not intend to discuss.
Russell J. Hopp, DO, FAAP	Yes	Astra-Zeneca, Glaxo-Smith-Kline, Schering-Plough, Sanofi-Aventis – speakers bureaus	No	Do not intend to discuss.
Peter F. Hoyer, MD	No	None	No	Do not intend to discuss.
Hal B. Jenson, MD, MBA, FAAP	Yes	Merck Vaccines – member of vaccine advisory board, speaker; Sanofi Pasteur - speaker	It is likely that reference to commercial products will occur occasionally. Commercial products are almost always discussed using the generic drug name and not the trade name. Trade names are used usually only if the commercial product is a fixed combination of multiple generic drugs.	It is likely that such use would be discussed occasionally. There are numerous widely used and generally accepted and recommended “off-label” uses for many drugs, especially in pediatrics. If “off-label” use is discussed in the text then it is stated as such.
Chris Plauche Johnson, MD, MEd, FAAP	No	None	Not sure	Many medications in autism are used off-label, and I state that.

J. Jeffrey Malatack, MD, FAAP	No	American Board of Pediatrics – member	No	Do not intend to discuss.
Blaise A. Nemeth, MD, MS, FAAP	No	None	Not sure	Do not intend to discuss.
John Pascoe, MD, FAAP	No	None	No	Do not intend to discuss.
DeWayne Pursley, MD, FAAP	-	-	-	-
Matthew D. Sadof, MD, FAAP	No	None	No	Do not intend to discuss.
Thomas T. Sato, MD, FAAP	No	None	No	Do not intend to discuss.
Bennett A. Shaywitz, MD, FAAP	Yes	Eli Lilly Co. – speaker / consultant	Yes, if relevant	N/A
Michael Silberbach, MD, FAAP	No	None	No	Do not intend to discuss.
Mark L. Silen, MD, FAAP	-	-	-	-
David L. Skaggs, MD, FAAP	Yes	Medtronics, Stryker Spine – consultant, speaker, research grant	No	Do not intend to discuss.
Nancy D. Spector, MD, FAAP	No	None	No	Do not intend to discuss.
Dan W. Thomas, MD, FAAP	No	N/A	No	Do not intend to discuss.
Surendra K. Varma, MD, FAAP	No	None	No	Do not intend to discuss.